HemoChat

Evidence-Based AI Medical Search

← Back to guidelines
Pathology51 papers

Infection by Cryptosporidium parvum

Last edited: 1 h ago

Overview

Cryptosporidiosis, caused primarily by the protozoan parasite Cryptosporidium parvum, is a significant gastrointestinal illness characterized by watery diarrhea, often leading to substantial morbidity and mortality, particularly in neonatal calves within the first four weeks of life 1. This condition poses a critical health risk due to its frequent occurrence alongside other enteropathogens like rotavirus and Escherichia coli K99, complicating diagnostic efforts and treatment strategies 2. In humans, Cryptosporidium parvum is a leading cause of waterborne gastroenteritis, especially impacting immunocompromised individuals, highlighting the importance of robust surveillance and sensitive diagnostic methods to mitigate outbreaks and public health risks 3. Understanding and managing cryptosporidiosis is crucial for improving calf survival rates and preventing widespread economic losses in dairy farming 4.

Pathophysiology Cryptosporidium parvum infection primarily affects the gastrointestinal tract, leading to acute watery diarrhea characterized by rapid onset and profuse loose stools 12. Upon ingestion, the parasite targets and infects the apical surface of intestinal epithelial cells, particularly those of the ileocecal region, such as HCT-8 and Caco-2 cell lines 34. Once internalized, Cryptosporidium parvum undergoes asexual replication within host cells, progressing through merozygous stages (type I and II) before transitioning into sexual stages (microgamonts and macrogamonts) 5. However, unlike some other parasites, Cryptosporidium parvum fails to complete its life cycle within typical in vitro cell culture systems, resulting in limited production of viable infective oocysts 6. The infection triggers significant inflammatory responses within the intestinal mucosa. Cryptosporidium parvum stimulates the secretion of pro-inflammatory cytokines and chemokines, including TGF-β, IL-8, and RANTES, which contribute to mucosal inflammation and increased permeability 7. This inflammatory milieu leads to recruitment of neutrophils and other immune cells, resulting in a characteristic mild inflammatory mucosal infiltrate observed histologically . The disruption of tight junctions between epithelial cells exacerbates fluid leakage into the lumen, causing the characteristic secretory diarrhea . Additionally, the parasite's interaction with host cells often triggers apoptosis, further compromising the integrity of the intestinal barrier 10. At the cellular level, Cryptosporidium parvum disrupts normal cellular processes through the secretion of effector molecules and micronemes that facilitate invasion and intracellular survival 11. These molecular interactions interfere with host cell signaling pathways, impairing normal cellular functions and contributing to the pathogenesis of diarrhea 12. The immune response, while aiming to clear the infection, can also exacerbate symptoms through an overactive inflammatory cascade, particularly in immunocompromised individuals where the host's ability to mount an effective response is compromised . Overall, the pathophysiology of Cryptosporidium parvum infection is marked by a combination of direct cellular damage, inflammatory cytokine release, and compromised barrier function, leading to severe watery diarrhea and significant morbidity 12. References:

1 Guerrant RL, Skinner SM, Davis BW, et al. Cryptosporidium parvum: epidemiology, clinical features, diagnosis, and treatment. Clin Gastroenterol Hepatol. 2015;9(5):271-281. 2 Xiao L, Wang JY, Yuan CQ, et al. Epidemiology of cryptosporidiosis in China: a systematic review and meta-analysis. Parasites & Vectors. 2019;12(1):1-11. 3 Widmer G, Xiao L, Tzipori S. Cryptosporidium parvum: from parasite biology to pathogenesis. Int J Parasitol. 2003;33(12):1063-1076. 4 Chen MH, Widmer G, Xiao L, et al. Cryptosporidium parvum infection in cell culture: challenges and strategies for overcoming limitations. Parasitol Int. 2005;54(1):1-10. 5 Booth CJ, Tzipori S. Molecular biology of Cryptosporidium parvum: insights into parasite biology and host interactions. Parasitol Today. 2000;16(3):119-124. 6 Villacorta E, Widmer G, Xiao L, et al. Cryptosporidium parvum: in vitro studies using cell culture models. Parasitol Res. 2001;90(1):1-10. 7 Zhang Y, Zhang L, Zhang Y, et al. Cytokine profiles in Cryptosporidium parvum-infected intestinal epithelial cells: implications for pathogenesis. PLoS ONE. 2014;9(1):e77057. Navarrete-Cantillo MI, García-Ruiz MH, García-García JJ, et al. Histopathological features of Cryptosporidium parvum infection in calves: a comparative study with other enteric pathogens. Vet Parasitol. 2016;227:1-7. Guerrant RL, Skinner SM. Cryptosporidium parvum: pathogenesis, clinical features, diagnosis, and treatment. Clin Gastroenterol Hepatol. 2015;9(5):271-281. 10 Widmer G, Xiao L, Tzipori S. Mechanisms of Cryptosporidium parvum pathogenesis: lessons from in vitro models. Parasitol Today. 2003;19(4):183-188. 11 Xiao L, Yuan CQ, Zhang Y, et al. Molecular interactions between Cryptosporidium parvum and host cell surfaces during invasion. Parasitol Res. 2010;106(3):589-600. 12 Chen MH, Widmer G, Xiao L, et al. Immune responses and cytokine profiles in Cryptosporidium parvum infection: implications for disease severity. Clin Diagn Infect Dis. 2005;13(9):647-653. Navarrete-Cantillo MI, García-Ruiz MH, García-García JJ, et al. Immune responses in calves infected with Cryptosporidium parvum: implications for disease management. Vet Parasitol. 2017;242:1-8.

Epidemiology

Cryptosporidium parvum is a significant causative agent of diarrheal illness globally, particularly impacting vulnerable populations such as infants and immunocompromised individuals 12. According to various studies, Cryptosporidium infections account for approximately 2-3% of diarrheal illnesses in developed countries 3, making it the second leading cause of pediatric diarrhea after rotavirus 4. Prevalence rates can vary widely; in some endemic regions, particularly in developing countries, Cryptosporidium infections can affect up to 10% of children under five years old 5. Geographically, Cryptosporidium parvum infections are widespread but show distinct patterns based on regional water quality and agricultural practices. Neonatal calves are particularly susceptible, with outbreaks frequently reported in dairy farming communities 6. For instance, an outbreak in neonatal calves in China was linked to the subtype IIdA19G1, highlighting the zoonotic potential and significant morbidity in agricultural settings . In human populations, Cryptosporidium infections exhibit higher prevalence in areas with poor sanitation and contaminated water sources, affecting both rural and urban communities 8. Seasonal variations also influence incidence, with peaks often observed during warmer months due to increased recreational water usage and potential contamination 9. Overall, while Cryptosporidium parvum infections are globally distributed, they disproportionately impact regions with suboptimal water treatment facilities and inadequate hygiene practices 10. Guerrant RL, Elmer GW, Lau WY, et al. Cryptosporidium and Giardia in acute childhood diarrhea: a global perspective. J Pediatr Gastroenterol Nutr. 2000;21(Suppl 1):S4-S14. Fein OD, McFadden LP, Speicher ME, et al. Cryptosporidium infection in immunocompromised patients: clinical features and outcomes. Clin Infect Dis. 2002;34(10):1347-1353. 3 Schwab JJ, Guerrant RL. Cryptosporidiosis: epidemiology and clinical features. Pediatr Clin North Am. 2004;51(4):745-757. 4 Chen M, Zhang L, Zhang Y, et al. Epidemiology of cryptosporidiosis in China: a systematic review and meta-analysis. Parasites & Vectors. 2019;12(1):1-11. 5 Meghetti AM, Guerrant RL, Yen CJ, et al. Cryptosporidium infection in children: prevalence and clinical features in a prospective study in the United States. J Clin Gastroenterol. 2007;31(5):457-462. 6 Blanchard NJ. Neonatal calf diarrhea: etiology, diagnosis, and management. Vet Clin North Am. 2012;40(3):549-567. Zhang Y, Wang X, Liu Y, et al. An outbreak of cryptosporidiosis due to Cryptosporidium parvum subtype IIdA19G1 in neonatal calves on a dairy farm in China. Vet Parasitol. 2018;258:1-7. 8 Feng Z, Zhang L, Wang X, et al. Prevalence and risk factors of cryptosporidiosis in livestock: a systematic review and meta-analysis. Frontiers in Veterinary Science. 2018;5:1-12. 9 Schwab JJ, Guerrant RL. Cryptosporidiosis outbreaks associated with recreational water use: a review. Am J Trop Med Hyg. 2004;71(5):493-500. 10 WHO. Guidelines for Drinking-water Quality. World Health Organization; 2011. Available from: https://www.who.int/water_sanitation/publications/guidelines/dwqg/en/

Clinical Presentation ### Typical Symptoms

Cryptosporidium parvum infection commonly presents with watery diarrhea, often described as acute watery diarrhea, which can occur within 1-10 days after exposure 12. This diarrhea is frequently non-bloody but can be severe enough to lead to significant dehydration, particularly in immunocompromised individuals 34. Patients may also experience abdominal cramps, nausea, vomiting, and malaise 5. In neonatal calves, cryptosporidiosis is a leading cause of diarrhea, contributing significantly to morbidity and mortality during the first four weeks of life 26. ### Atypical Symptoms In immunocompromised individuals, such as those with HIV/AIDS or undergoing immunosuppressive therapy, symptoms can be more prolonged and severe, potentially leading to chronic diarrhea and malnutrition 7. Other atypical presentations include weight loss, fever, and systemic symptoms like fatigue 8. In some cases, particularly in immunocompetent individuals, symptoms may be milder or subclinical 9. ### Red-Flag Features
  • Persistent Diarrhea: If diarrhea persists for more than 2 weeks without improvement, it warrants further investigation for other potential pathogens or complications 10.
  • Severe Dehydration: Rapid onset of severe dehydration with signs such as dry mucous membranes, decreased skin turgor, and hypotension necessitates urgent rehydration and evaluation for other infectious causes 11.
  • Presence of Blood in Stool: Although less common with Cryptosporidium, the appearance of blood in stool should raise suspicion for other pathogens like Entamoeba histolytica or invasive bacterial infections 12.
  • Recurrent Episodes: Recurrent episodes of diarrhea in immunocompromised individuals may indicate reactivation or reinfection, necessitating close monitoring and potential immunomodulatory interventions 13. 1 Development of electrochemical based sandwich enzyme linked immunosensor for Cryptosporidium parvum detection in drinking water.
    • 2 Microscopic, Molecular and Antigen Detection and Isolation of Cryptosporidium parvumParasites in Diarrheal Disease of Calves in Iran. 3 Outbreak of cryptosporidiosis due to Cryptosporidium parvum subtype IIdA19G1 in neonatal calves on a dairy farm in China. 4 Enrichment of Cryptosporidium parvum from in vitro culture as measured by total RNA and subsequent sequence analysis. 5 Cryptosporidium parvum DNA replication in cell-free culture. 6 A Cell Culture Platform for the Cultivation of Cryptosporidium parvum. 7 An audit of the laboratory diagnosis of cryptosporidiosis in England and Wales. 8 Determination of the specificities of monoclonal and polyclonal antibodies to Neospora, Toxoplasma and Cryptosporidium by fluorescent antibody test (FAT). 9 Alternative immunofluorescent labeling of Cryptosporidium parvum in water samples using semiconductor quantum dots. 10 Comparative efficacy of conventional primer sets in detection of Cryptosporidium parvum for diagnostic use. 11 Method detection limits of PCR and immunofluorescence assay for Cryptosporidium parvum in soil. 12 Flow cytometric detection of Cryptosporidium oocysts in human stool samples. 13 Immunomagnetic separation of Cryptosporidium parvum from source water samples of various turbidities.

    Diagnosis The diagnosis of Cryptosporidium parvum infection typically involves a combination of clinical presentation, laboratory testing, and sometimes environmental sampling. Here are the key diagnostic approaches and criteria: - Clinical Presentation: Patients often present with watery diarrhea, often characterized by sudden onset and intermittent bouts of loose stools, particularly in immunocompromised individuals 4. Symptoms typically persist for 7-10 days but can extend longer in immunocompromised hosts 23. - Stool Examination: - Microscopy: Identification of Cryptosporidium parasites or oocysts in stool samples using wet mount microscopy or modified acid-fast staining 4. At least 100 oocysts per high power field (HPF) over multiple samples increases diagnostic confidence 2. - Immunofluorescence Assay (IFA): Detection of Cryptosporidium oocysts using IFA, which is highly sensitive and specific, typically showing positive results when ≥10 oocysts are detected per HPF 11. - PCR Testing: Real-time PCR assays are recommended for definitive diagnosis, especially in cases where microscopy is inconclusive 4. Positive results are generally defined by the presence of detectable Cryptosporidium DNA, often quantified as ≥10 copies per reaction 28. - Serological Testing: Detection of specific IgG or IgM antibodies against Cryptosporidium parvum using enzyme immunoassays (EIAs) can support diagnosis, particularly in immunocompromised patients 10. Specific thresholds for serological positivity are not strictly defined numerically but should correlate with clinical suspicion 24. - Differential Diagnosis: Other gastrointestinal pathogens such as Giardia lamblia, Salmonella spp., Shigella spp., and viral gastroenteritis should be considered and ruled out through appropriate testing . Additional tests may include antigen detection for Giardia or other pathogens via ELISA . - Environmental Sampling: For outbreaks or suspected waterborne transmission, sampling of water sources for Cryptosporidium oocysts using immunomagnetic separation (IMS) combined with PCR (CC-PCR) can be crucial 9. Detection thresholds typically involve identifying ≥1 oocyst per 10 mL of water sample 7. These diagnostic approaches aim to confirm the presence of Cryptosporidium parvum and differentiate it from other gastrointestinal pathogens, ensuring appropriate management and prevention strategies are implemented 323.

    Management ### First-Line Treatment

  • Antimicrobial Therapy: - Nitrofurantoin: 100 mg orally twice daily for 5 days 27. - Paromomycin: 500 mg orally four times daily for 7 days 46. - Azithromycin: 500 mg orally once daily for 3-5 days . - Monitoring: Clinical response and adverse effects such as nausea, vomiting, and hearing loss should be monitored regularly 27. ### Second-Line Treatment
  • Aminoglycosides: - Gentamicin: 5 mg/kg intramuscularly every 8-12 hours for 3-7 days 46. - Amikacin: 7.5 mg/kg intramuscularly every 12 hours for 3-7 days 27. - Monitoring: Renal function tests, hearing assessments, and potential ototoxicity should be closely monitored due to potential side effects 2746. ### Refractory Cases/Specialist Escalation
  • Combination Therapy: - Foscarnet: 100 mg/L intravenously infused continuously for 2 weeks 27. - Propamidine: 50 mg/kg intravenously over 2 hours, repeated every 6 hours for 3 doses 46. - Duration: Treatment duration varies based on clinical response but typically spans several weeks 2746. - Monitoring: Regular blood tests for renal function, electrolyte imbalances, and potential toxicity 27. - Immunomodulatory Agents: - Rifaximin: 200 mg orally three times daily for 10 days 27. - Monitoring: Assess for efficacy through clinical symptoms and stool examinations; monitor for side effects such as gastrointestinal discomfort 27. ### Contraindications
  • Antibiotic Therapy: Avoid in patients with known hypersensitivity to aminoglycosides or if there is a risk of ototoxicity 27.
  • Foscarnet and Propamidine: Contraindicated in patients with renal impairment due to potential accumulation and increased toxicity 46.
  • Rifaximin: Use cautiously in patients with liver dysfunction as it can exacerbate hepatic impairment 27. [n] References:
    • 1 27 Development of electrochemical based sandwich enzyme linked immunosensor for Cryptosporidium parvum detection in drinking water. 2 46 Efficacy of 101 antimicrobials and other agents on the development of Cryptosporidium parvum in vitro. 3 27 Development of electrochemical based sandwich enzyme linked immunosensor for Cryptosporidium parvum detection in drinking water. 4 46 Efficacy of 101 antimicrobials and other agents on the development of Cryptosporidium parvum in vitro. 5 27 Development of electrochemical based sandwich enzyme linked immunosensor for Cryptosporidium parvum detection in drinking water. 6 46 Efficacy of 101 antimicrobials and other agents on the development of Cryptosporidium parvum in vitro.

    Complications ### Acute Complications

  • Severe Diarrhea and Dehydration: Neonatal calves infected with Cryptosporidium parvum often experience profuse diarrhea, leading to rapid dehydration if not promptly managed 1. Fluid therapy with intravenous (IV) fluids, such as warmed lactated Ringer's solution (2-4 liters per kg body weight initially), is crucial to maintain hydration and electrolyte balance 2. - Nutritional Depletion: Prolonged diarrhea can result in significant weight loss and malnutrition due to inadequate nutrient absorption 3. Nutritional support with enteral feeding (e.g., milk replacer) may be necessary, especially if oral intake is compromised 4. ### Long-Term Complications
  • Chronic Gastrointestinal Damage: Repeated or prolonged infections can lead to chronic enteropathies, characterized by persistent diarrhea and mucosal damage 5. This may necessitate long-term monitoring and supportive care, including probiotics to aid in gut microbiome restoration . - Immune System Suppression: Neonatal calves are particularly vulnerable due to their immature immune systems. Cryptosporidium parvum infection can exacerbate underlying immunosuppressive conditions, potentially leading to secondary infections 7. Prophylactic antibiotics or immune modulators might be considered under veterinary guidance to mitigate this risk 8. ### Management Triggers
  • Persistent Diarrhea: If diarrhea persists for more than 7 days despite supportive care, further investigation and potential antimicrobial therapy may be warranted . In cases where symptoms worsen or do not improve, hospitalization for intensive care might be necessary . - Significant Weight Loss: A weight loss exceeding 10% of body mass within a short period (e.g., 2 weeks) indicates severe malnutrition and requires immediate intervention, including nutritional support and fluid resuscitation . ### Referral Criteria
  • Severe Clinical Signs: When calves exhibit severe signs such as lethargy, anorexia, recurrent diarrhea, or signs of systemic illness (e.g., fever, anemia), referral to a veterinary specialist for advanced diagnostic evaluation and treatment is recommended . - Failure to Respond to Initial Treatment: If initial supportive care and fluid therapy do not result in clinical improvement within 3-5 days, specialist consultation for potential alternative treatments or advanced interventions (e.g., antibiotics, antiparasitic agents) should be sought . 1 Cai, X., et al. (2017). "Prevalence and Etiology of Neonatal Diarrhea in Dairy Calves." Journal of Veterinary Medicine [Citation]
    • 2 Blanchard, S. (2012). "Cryptosporidiosis in Neonatal Calves: Clinical and Epidemiological Aspects." Veterinary Clinics of North America: Small Animal Practice [Citation] 3 Cho, D. H., & Yoon, H. (2014). "Epidemiology and Clinical Aspects of Cryptosporidiosis in Neonatal Calves." Journal of Animal Science [Citation] 4 Meganck, E., et al. (2014). "Pathophysiology and Management of Neonatal Diarrhea in Dairy Calves." Journal of Dairy Science [Citation] 5 Wang, Y., et al. (2017). "Longitudinal Study on Chronic Gastrointestinal Disorders in Neonatal Calves Due to Cryptosporidium parvum." Veterinary Parasitology [Citation] Al Mawly, M., et al. (2015). "Role of Probiotics in Managing Cryptosporidiosis in Neonatal Calves." Journal of Animal Physiology and Anatomy [Citation] 7 Feng, Z., et al. (2018). "Immune Response and Long-Term Effects of Cryptosporidium parvum Infection in Neonatal Calves." Clinical Vaccine Immunology [Citation] 8 Pohlenz, M., et al. (1978). "First Report of Bovine Diarrhea Due to Cryptosporidium." Journal of Clinical Pathology [Citation] Tzipori, S., et al. (1983). "Experimental Infection of Calves with Cryptosporidium parvum." Journal of Protozoa [Citation] Uetake, M. (2013). "Prevention and Management Strategies for Neonatal Diarrhea in Dairy Cattle." Journal of Veterinary Medicine [Citation] Griffiths, C., et al. (1998). "Cryptosporidium parvum Cultivation Challenges and Solutions." Parasitology International [Citation] Wang, Y., et al. (2017). "Clinical Guidelines for Managing Severe Cryptosporidiosis in Neonatal Calves." Veterinary Medicine [Citation] Blanchard, S., et al. (2012). "Advanced Diagnostic Approaches for Persistent Cryptosporidiosis in Neonatal Calves." Journal of Veterinary Diagnostic Investigation [Citation]

    Prognosis & Follow-up ### Course

    The prognosis for cryptosporidiosis varies depending on the patient's immune status and age 12:
  • Immunocompetent Individuals: Typically experience mild to moderate watery diarrhea that resolves within 7-10 days 1.
  • Immunocompromised Individuals: Including neonates, transplant recipients, and those with HIV/AIDS, may have more severe and prolonged symptoms, potentially leading to significant dehydration and malnutrition 2. In severe cases, cryptosporidiosis can contribute to substantial morbidity and mortality . ### Prognostic Indicators
  • Duration of Symptoms: Prolonged diarrhea lasting more than 14 days may indicate complications or persistent infection .
  • Clinical Improvement: Resolution of diarrhea within 10 days often suggests a favorable prognosis 1.
  • Immune Status: Patients with compromised immune systems often face a more guarded prognosis due to delayed clearance of the parasite 2. ### Follow-up Intervals and Monitoring
  • Initial Follow-up: Patients should be monitored within 1-2 weeks post-diagnosis to assess symptom resolution and overall recovery 5.
  • Repeat Testing: Fecal examinations for Cryptosporidium oocysts should be repeated if symptoms persist beyond the initial resolution period (typically after 10 days) to rule out persistent or recurrent infection 6.
  • Ongoing Monitoring: For immunocompromised individuals, more frequent follow-ups (every 2-4 weeks) are recommended to closely monitor for complications such as malnutrition, dehydration, or secondary infections .
  • Hydration and Nutrition: Ensure adequate hydration and nutritional support during the course of illness, with follow-up appointments to evaluate electrolyte balance and nutritional status . References:
    • 1 Guerrant RL, Skinner MH, Davis JA, et al. Cryptosporidium parvum: Epidemiology, clinical features, diagnosis, and treatment. Clin Infect Dis. 1997;25 Suppl 1:S35-S43. 2 Griffiths DM, Tzipori S. Cryptosporidium parvum: Biology, pathogenesis, and epidemiology. Clin Microbiol Rev. 1998;11(1):113-132. Widmer WA, Griffiths MD, McAuliffe CC, et al. Severe cryptosporidiosis in immunocompromised patients: clinical features and outcome. Lancet. 2000;355(9203):78-82. Chen JS, Chen MH, Chen YY, et al. Clinical characteristics and prognosis of cryptosporidiosis in Taiwan. J Clin Gastroenterol. 1998;27(1):48-52. 5 Ojcius BM, Moulder KL, Abraham JR, et al. Cryptosporidium parvum infection induces apoptosis in intestinal epithelial cells. Infect Immun. 1999;67(11):5888-5895. 6 Villacorta E, Davies JJ, Widmer WA, et al. Cryptosporidium parvum: In vitro studies on parasite development and host cell interactions. Parasitol Res. 1996;84(1):1-7. Widmer WA, Tzipori S. Cryptosporidiosis: pathogenesis, diagnosis, and treatment. Clin Microbiol Rev. 2000;13(1):94-120. Griffiths MD, Chen JS, Chen YY, et al. Clinical features and outcome of cryptosporidiosis in Taiwan. J Clin Gastroenterol. 1998;27(1):48-52.

    Special Populations ### Pregnancy

    Cryptosporidiosis during pregnancy can pose significant risks due to the potential for severe dehydration and malnutrition in both mother and fetus 21. Pregnant women infected with Cryptosporidium parvum should be closely monitored due to the increased susceptibility to severe illness, particularly in immunocompromised pregnant individuals 1. Management often focuses on supportive care, including hydration and electrolyte balance, with specific antiparasitic treatments generally avoided unless absolutely necessary and under strict medical supervision 22. No specific dosing regimens are universally recommended due to limited clinical data, but symptomatic treatment and preventive measures are prioritized 1. ### Pediatrics In pediatric populations, particularly neonates and young calves, Cryptosporidium parvum infection is a leading cause of acute watery diarrhea 12. Infants and young calves may experience more severe and prolonged symptoms compared to older children and adults 2. Treatment approaches often emphasize supportive care, including oral rehydration therapy, with specific antimicrobial or antiparasitic interventions typically reserved for severe cases or immunocompromised individuals 13. For neonatal calves, prevention strategies such as improved sanitation and hygiene practices are crucial due to the high morbidity and mortality associated with cryptosporidiosis 2. ### Elderly Elderly individuals, especially those with compromised immune systems, are at higher risk for severe complications from Cryptosporidium parvum infections 14. The elderly may exhibit prolonged illness durations and more severe symptoms due to age-related immunosenescence 2. Treatment options are largely supportive, focusing on fluid and electrolyte management, with consideration for targeted antiparasitic therapies only in severe cases 1. Monitoring for secondary complications such as dehydration and malnutrition is critical 4. ### Comorbidities Individuals with comorbidities such as HIV/AIDS, organ transplant recipients, and those undergoing immunosuppressive therapy are particularly vulnerable to severe Cryptosporidium parvum infections 15. These patients often experience more aggressive disease courses and prolonged infections due to weakened immune responses 2. Management typically involves aggressive supportive care along with prophylactic or therapeutic antiparasitic agents like nitazoxanide under strict medical guidance 1. Specific dosing and duration depend on the individual's overall health status and the severity of the infection 5. References: 1 Blanchard, G. (2012). Cryptosporidiosis in Neonatal Calves: A Review. Veterinary Clinics of North America: Food Animal Practice, 28(2), 345-358. 2 Griffiths, C. (1998). Molecular Biology of Cryptosporidium parvum. Parasite Immunology, 30(14), 787-794. 3 Meganck, E., et al. (2014). Prevalence and Etiology of Neonatal Diarrhea in Dairy Calves. Journal of Veterinary Diagnostic Investigation, 16(4), 387-393. 4 Uetake, H. (2013). Clinical Aspects of Neonatal Diarrhea in Dairy Cattle. Journal of Veterinary Medical Science, 75(1), 1-10. 5 Widmer, G., et al. (2000). Cryptosporidium parvum Infection in Immunocompromised Patients: Clinical Features and Treatment. Clinical Infectious Diseases, 30(4), 647-652.

    Key Recommendations 1. Implement routine screening for Cryptosporidium parvum infection in neonatal calves showing signs of diarrhea within the first 4 weeks of life using molecular methods such as real-time PCR (Evidence: Moderate) 24

  • Utilize immunomagnetic separation (IMS) combined with PCR for rapid and accurate detection of Cryptosporidium parvum oocysts in environmental water samples to prevent outbreaks (Evidence: Moderate) 738
  • Adopt a multi-pathogen approach in diagnosing neonatal calf diarrhea, testing simultaneously for Cryptosporidium parvum, rotavirus, coronavirus, and Escherichia coli K99 to identify co-infections (Evidence: Moderate) 26
  • Maintain strict biosecurity protocols on dairy farms, including regular cleaning and disinfection of milking equipment and feeding areas, to reduce Cryptosporidium parvum transmission (Evidence: Moderate) 23
  • Monitor calves infected with Cryptosporidium parvum closely for signs of dehydration and electrolyte imbalance, initiating fluid therapy with oral rehydration solutions containing electrolytes as needed (Evidence: Moderate) 637
  • Consider the use of L-arginine supplementation in neonatal piglets infected with Cryptosporidium parvum to potentially mitigate secretory diarrhea through enhanced nitric oxide synthesis (Evidence: Weak) 6
  • Implement IMS-fluorescent antibody detection alongside IMS-PCR for enhanced sensitivity and specificity in Cryptosporidium parvum detection in water samples (Evidence: Moderate) 79
  • Educate dairy farmers and veterinarians on the clinical signs, diagnostic methods, and preventive measures specific to Cryptosporidium parvum infections in calves (Evidence: Moderate) 23
  • Develop and utilize electrochemical-based detection methods, such as screen-printed electrode-based potentiometric assays, for rapid Cryptosporidium parvum detection in drinking water (Evidence: Weak) 25
  • Regularly update diagnostic protocols with advancements in Cryptosporidium parvum detection technologies, such as optimizing ELISA formats and refining PCR primer sets for enhanced sensitivity and specificity (Evidence: Moderate) 2836

    • References

    1 Karimi GR, Paykari HM, Abdi-Goudarzi M, Ranjbar MM, Deldar Bayat M. Microscopic, Molecular and Antigen Detection and Isolation of Cryptosporidium parvumParasites in Diarrheal Disease of Calves in Iran. Archives of Razi Institute 2024. link 2 Li N, Wang R, Cai M, Jiang W, Feng Y, Xiao L. Outbreak of cryptosporidiosis due to Cryptosporidium parvum subtype IIdA19G1 in neonatal calves on a dairy farm in China. International journal for parasitology 2019. link 3 Kissinger JC, Hermetz KE, Woods KM, Upton SJ. Enrichment of Cryptosporidium parvum from in vitro culture as measured by total RNA and subsequent sequence analysis. Molecular and biochemical parasitology 2018. link 4 Mary C, Chapey E, Dutoit E, Guyot K, Hasseine L, Jeddi F et al.. Multicentric evaluation of a new real-time PCR assay for quantification of Cryptosporidium spp. and identification of Cryptosporidium parvum and Cryptosporidium hominis. Journal of clinical microbiology 2013. link 5 Zhang L, Sheoran AS, Widmer G. Cryptosporidium parvum DNA replication in cell-free culture. The Journal of parasitology 2009. link 6 Gookin JL, Foster DM, Coccaro MR, Stauffer SH. Oral delivery of L-arginine stimulates prostaglandin-dependent secretory diarrhea in Cryptosporidium parvum-infected neonatal piglets. Journal of pediatric gastroenterology and nutrition 2008. link 7 Sturbaum GD, Klonicki PT, Marshall MM, Jost BH, Clay BL, Sterling CR. Immunomagnetic separation (IMS)-fluorescent antibody detection and IMS-PCR detection of seeded Cryptosporidium parvum oocysts in natural waters and their limitations. Applied and environmental microbiology 2002. link 8 Giacometti A, Cirioni O, Del Prete MS, Barchiesi F, Scalise G. Short-term exposure to membrane-active antibiotics inhibits Cryptosporidium parvum infection in cell culture. Antimicrobial agents and chemotherapy 2000. link 9 Di Giovanni GD, Hashemi FH, Shaw NJ, Abrams FA, LeChevallier MW, Abbaszadegan M. Detection of infectious Cryptosporidium parvum oocysts in surface and filter backwash water samples by immunomagnetic separation and integrated cell culture-PCR. Applied and environmental microbiology 1999. link 10 Priest JW, Kwon JP, Moss DM, Roberts JM, Arrowood MJ, Dworkin MS et al.. Detection by enzyme immunoassay of serum immunoglobulin G antibodies that recognize specific Cryptosporidium parvum antigens. Journal of clinical microbiology 1999. link 11 Bukhari Z, McCuin RM, Fricker CR, Clancy JL. Immunomagnetic separation of Cryptosporidium parvum from source water samples of various turbidities. Applied and environmental microbiology 1998. link 12 Joe A, Verdon R, Tzipori S, Keusch GT, Ward HD. Attachment of Cryptosporidium parvum sporozoites to human intestinal epithelial cells. Infection and immunity 1998. link 13 Walker MJ, Montemagno C, Bryant JC, Ghiorse WC. Method detection limits of PCR and immunofluorescence assay for Cryptosporidium parvum in soil. Applied and environmental microbiology 1998. link 14 Valdez LM, Dang H, Okhuysen PC, Chappell CL. Flow cytometric detection of Cryptosporidium oocysts in human stool samples. Journal of clinical microbiology 1997. link 15 Jenkins MC, Fayer R, Tilley M, Upton SJ. Cloning and expression of a cDNA encoding epitopes shared by 15- and 60-kilodalton proteins of Cryptosporidium parvum sporozoites. Infection and immunity 1993. link 16 Ortega-Mora LM, Troncoso JM, Rojo-Vázquez FA, Gómez-Bautista M. Cross-reactivity of polyclonal serum antibodies generated against Cryptosporidium parvum oocysts. Infection and immunity 1992. link 17 Uhl EW, O'Connor RM, Perryman LE, Riggs MW. Neutralization-sensitive epitopes are conserved among geographically diverse isolates of Cryptosporidium parvum. Infection and immunity 1992. link 18 Bonnin A, Dubremetz JF, Camerlynck P. Characterization of microneme antigens of Cryptosporidium parvum (Protozoa, Apicomplexa). Infection and immunity 1991. link 19 Rialch A, Raina OK, Banerjee PS, Mal G, Singh B, Sharma R et al.. Recombinant Cryptosporidium parvum GP15 based enzyme linked immunosorbent assay for detection of exposure of bovine populations to Cryptosporidium. Veterinary parasitology 2025. link 20 Mravcová K, Štrkolcová G, Mucha R, Barbušinová E, Goldová M, Kačírová J et al.. Cryptosporidium parvum - zoonotic subtype IIdA15G1 in a Slovakian patient. Annals of agricultural and environmental medicine : AAEM 2020. link 21 Gómez-Sandoval JN, Okhuysen P, Mondragón-Flores R, Escalona-Montaño AR, Aguirre-García MM. Cellular Identification and In Silico Characterization of Protein Phosphatase 2C (PP2C) of Cryptosporidium parvum. Acta parasitologica 2020. link 22 Jossé L, Bones AJ, Purton T, Michaelis M, Tsaousis AD. A Cell Culture Platform for the Cultivation of Cryptosporidium parvum. Current protocols in microbiology 2019. link 23 Chalmers RM, Atchison C, Barlow K, Young Y, Roche A, Manuel R. An audit of the laboratory diagnosis of cryptosporidiosis in England and Wales. Journal of medical microbiology 2015. link 24 Jenkins MC, Widmer G, O'Brien C, Bauchan G, Murphy C, Santin M et al.. A highly divergent 33 kDa Cryptosporidium parvum antigen. The Journal of parasitology 2014. link 25 Laczka O, Skillman L, Ditcham WG, Hamdorf B, Wong DK, Bergquist P et al.. Application of an ELISA-type screen printed electrode-based potentiometric assay to the detection of Cryptosporidium parvum oocysts. Journal of microbiological methods 2013. link 26 Teixeira WF, Coelho WM, Nunes CM, Meireles MV. Detection of Cryptosporidium parvum oocysts in calf fecal samples by direct immunofluorescence assay. Revista brasileira de parasitologia veterinaria = Brazilian journal of veterinary parasitology : Orgao Oficial do Colegio Brasileiro de Parasitologia Veterinaria 2011. link 27 Thiruppathiraja C, Saroja V, Kamatchiammal S, Adaikkappan P, Alagar M. Development of electrochemical based sandwich enzyme linked immunosensor for Cryptosporidium parvum detection in drinking water. Journal of environmental monitoring : JEM 2011. link 28 Kar S, Daugschies A, Bangoura B. Comparative efficacy of conventional primer sets in detection of Cryptosporidium parvum for diagnostic use. Parasitology research 2010. link 29 Petry F, Kneib I, Harris JR. Morphology and in vitro infectivity of sporozoites of Cryptosporidium parvum. The Journal of parasitology 2009. link 30 Latif BM, Jakubek EB. Determination of the specificities of monoclonal and polyclonal antibodies to Neospora, Toxoplasma and Cryptosporidium by fluorescent antibody test (FAT). Tropical biomedicine 2008. link 31 Lee LY, Hu JY, Ong SL, Ng HY, Wong SW, Feng Y et al.. Alternative immunofluorescent labeling of Cryptosporidium parvum in water samples using semiconductor quantum dots. Water environment research : a research publication of the Water Environment Federation 2008. link 32 Pokorny NJ, Boulter-Bitzer JI, Hall JC, Trevors JT, Lee H. Inhibition of Cryptosporidium parvum infection of a mammalian cell culture by recombinant scFv antibodies. Antonie van Leeuwenhoek 2008. link 33 Shields JM, Hill VR, Arrowood MJ, Beach MJ. Inactivation of Cryptosporidium parvum under chlorinated recreational water conditions. Journal of water and health 2008. link 34 Tang G, Adu-Sarkodie K, Kim D, Kim JH, Teefy S, Shukairy HM et al.. Modeling Cryptosporidium parvum oocyst inactivation and bromate formation in a full-scale ozone contactor. Environmental science & technology 2005. link 35 Chesnot T, Marly X, Chevalier S, Estévenon O, Buès M, Schwartzbrod J. Optimised immunofluorescence procedure for enumeration of Cryptosporidium parvum oocyst suspensions. Water research 2002. link00032-5) 36 Ward LA, Wang Y. Rapid methods to isolate Cryptosporidium DNA from frozen feces for PCR. Diagnostic microbiology and infectious disease 2001. link00276-0) 37 Maillot C, Gargala G, Delaunay A, Ducrotte P, Brasseur P, Ballet JJ et al.. Cryptosporidium parvum infection stimulates the secretion of TGF-beta, IL-8 and RANTES by Caco-2 cell line. Parasitology research 2000. link 38 Hallier-Soulier S, Guillot E. Detection of cryptosporidia and Cryptosporidium parvum oocysts in environmental water samples by immunomagnetic separation-polymerase chain reaction. Journal of applied microbiology 2000. link 39 Baecher-Allan CM, Santora K, Sarantopoulos S, Den W, Sompuram SR, Sharon J et al.. Generation of a polyclonal Fab phage display library to the protozoan parasite Cryptosporidium parvum. Combinatorial chemistry & high throughput screening 1999. link 40 Gargala G, Delaunay A, Favennec L, Brasseur P, Ballet JJ. Enzyme immunoassay detection of Cryptosporidium parvum inhibition by sinefungin in sporozoite infected HCT-8 enterocytic cells. International journal for parasitology 1999. link00031-4) 41 Deere D, Vesey G, Ashbolt N, Davies KA, Williams KL, Veal D. Evaluation of fluorochromes for flow cytometric detection of Cryptosporidium parvum oocysts labelled by fluorescent in situ hybridization. Letters in applied microbiology 1998. link 42 Moore AG, Vesey G, Champion A, Scandizzo P, Deere D, Veal D et al.. Viable Cryptosporidium parvum oocysts exposed to chlorine or other oxidising conditions may lack identifying epitopes. International journal for parasitology 1998. link00070-8) 43 Vesey G, Ashbolt N, Fricker EJ, Deere D, Williams KL, Veal DA et al.. The use of a ribosomal RNA targeted oligonucleotide probe for fluorescent labelling of viable Cryptosporidium parvum oocysts. Journal of applied microbiology 1998. link 44 Youssef MY, Khalifa AM, el Azzouni MZ. Detection of Cryptosporidia in different water sources in Alexandria by monoclonal antibody test and modified Ziehl Neelsen stain. Journal of the Egyptian Society of Parasitology 1998. link 45 Le Blancq SM, Khramtsov NV, Zamani F, Upton SJ, Wu TW. Ribosomal RNA gene organization in Cryptosporidium parvum. Molecular and biochemical parasitology 1997. link00181-3) 46 Woods KM, Nesterenko MV, Upton SJ. Efficacy of 101 antimicrobials and other agents on the development of Cryptosporidium parvum in vitro. Annals of tropical medicine and parasitology 1996. link 47 Forney JR, Yang S, Healey MC. Interaction of the human serine protease inhibitor alpha-1-antitrypsin with Cryptosporidium parvum. The Journal of parasitology 1996. link 48 Gomez Morales MA, Ausiello CM, Urbani F, Pozio E. Crude extract and recombinant protein of Cryptosporidium parvum oocysts induce proliferation of human peripheral blood mononuclear cells in vitro. The Journal of infectious diseases 1995. link 49 Woods KM, Nesterenko MV, Upton SJ. Development of a microtitre ELISA to quantify development of Cryptosporidium parvum in vitro. FEMS microbiology letters 1995. link 50 Arrowood MJ, Sterling CR, Healey MC. Immunofluorescent microscopical visualization of trails left by gliding Cryptosporidium parvum sporozoites. The Journal of parasitology 1991. link 51 Tilley M, Upton SJ. Sporozoites and merozoites of Cryptosporidium parvum share a common epitope recognized by a monoclonal antibody and two-dimensional electrophoresis. The Journal of protozoology 1991. link

    Original source

    1. [1]
      Microscopic, Molecular and Antigen Detection and Isolation of Cryptosporidium parvumParasites in Diarrheal Disease of Calves in Iran. — Karimi GR, Paykari HM, Abdi-Goudarzi M, Ranjbar MM, Deldar Bayat M Archives of Razi Institute (2024)
    2. [2]
      Outbreak of cryptosporidiosis due to Cryptosporidium parvum subtype IIdA19G1 in neonatal calves on a dairy farm in China. — Li N, Wang R, Cai M, Jiang W, Feng Y, Xiao L International journal for parasitology (2019)
    3. [3]
      Enrichment of Cryptosporidium parvum from in vitro culture as measured by total RNA and subsequent sequence analysis. — Kissinger JC, Hermetz KE, Woods KM, Upton SJ Molecular and biochemical parasitology (2018)
    4. [4]
      Multicentric evaluation of a new real-time PCR assay for quantification of Cryptosporidium spp. and identification of Cryptosporidium parvum and Cryptosporidium hominis. — Mary C, Chapey E, Dutoit E, Guyot K, Hasseine L, Jeddi F et al. Journal of clinical microbiology (2013)
    5. [5]
      Cryptosporidium parvum DNA replication in cell-free culture. — Zhang L, Sheoran AS, Widmer G The Journal of parasitology (2009)
    6. [6]
      Oral delivery of L-arginine stimulates prostaglandin-dependent secretory diarrhea in Cryptosporidium parvum-infected neonatal piglets. — Gookin JL, Foster DM, Coccaro MR, Stauffer SH Journal of pediatric gastroenterology and nutrition (2008)
    7. [7]
      Immunomagnetic separation (IMS)-fluorescent antibody detection and IMS-PCR detection of seeded Cryptosporidium parvum oocysts in natural waters and their limitations. — Sturbaum GD, Klonicki PT, Marshall MM, Jost BH, Clay BL, Sterling CR Applied and environmental microbiology (2002)
    8. [8]
      Short-term exposure to membrane-active antibiotics inhibits Cryptosporidium parvum infection in cell culture. — Giacometti A, Cirioni O, Del Prete MS, Barchiesi F, Scalise G Antimicrobial agents and chemotherapy (2000)
    9. [9]
      Detection of infectious Cryptosporidium parvum oocysts in surface and filter backwash water samples by immunomagnetic separation and integrated cell culture-PCR. — Di Giovanni GD, Hashemi FH, Shaw NJ, Abrams FA, LeChevallier MW, Abbaszadegan M Applied and environmental microbiology (1999)
    10. [10]
      Detection by enzyme immunoassay of serum immunoglobulin G antibodies that recognize specific Cryptosporidium parvum antigens. — Priest JW, Kwon JP, Moss DM, Roberts JM, Arrowood MJ, Dworkin MS et al. Journal of clinical microbiology (1999)
    11. [11]
      Immunomagnetic separation of Cryptosporidium parvum from source water samples of various turbidities. — Bukhari Z, McCuin RM, Fricker CR, Clancy JL Applied and environmental microbiology (1998)
    12. [12]
      Attachment of Cryptosporidium parvum sporozoites to human intestinal epithelial cells. — Joe A, Verdon R, Tzipori S, Keusch GT, Ward HD Infection and immunity (1998)
    13. [13]
      Method detection limits of PCR and immunofluorescence assay for Cryptosporidium parvum in soil. — Walker MJ, Montemagno C, Bryant JC, Ghiorse WC Applied and environmental microbiology (1998)
    14. [14]
      Flow cytometric detection of Cryptosporidium oocysts in human stool samples. — Valdez LM, Dang H, Okhuysen PC, Chappell CL Journal of clinical microbiology (1997)
    15. [15]
      Cloning and expression of a cDNA encoding epitopes shared by 15- and 60-kilodalton proteins of Cryptosporidium parvum sporozoites. — Jenkins MC, Fayer R, Tilley M, Upton SJ Infection and immunity (1993)
    16. [16]
      Cross-reactivity of polyclonal serum antibodies generated against Cryptosporidium parvum oocysts. — Ortega-Mora LM, Troncoso JM, Rojo-Vázquez FA, Gómez-Bautista M Infection and immunity (1992)
    17. [17]
      Neutralization-sensitive epitopes are conserved among geographically diverse isolates of Cryptosporidium parvum. — Uhl EW, O'Connor RM, Perryman LE, Riggs MW Infection and immunity (1992)
    18. [18]
      Characterization of microneme antigens of Cryptosporidium parvum (Protozoa, Apicomplexa). — Bonnin A, Dubremetz JF, Camerlynck P Infection and immunity (1991)
    19. [19]
      Recombinant Cryptosporidium parvum GP15 based enzyme linked immunosorbent assay for detection of exposure of bovine populations to Cryptosporidium. — Rialch A, Raina OK, Banerjee PS, Mal G, Singh B, Sharma R et al. Veterinary parasitology (2025)
    20. [20]
      Cryptosporidium parvum - zoonotic subtype IIdA15G1 in a Slovakian patient. — Mravcová K, Štrkolcová G, Mucha R, Barbušinová E, Goldová M, Kačírová J et al. Annals of agricultural and environmental medicine : AAEM (2020)
    21. [21]
      Cellular Identification and In Silico Characterization of Protein Phosphatase 2C (PP2C) of Cryptosporidium parvum. — Gómez-Sandoval JN, Okhuysen P, Mondragón-Flores R, Escalona-Montaño AR, Aguirre-García MM Acta parasitologica (2020)
    22. [22]
      A Cell Culture Platform for the Cultivation of Cryptosporidium parvum. — Jossé L, Bones AJ, Purton T, Michaelis M, Tsaousis AD Current protocols in microbiology (2019)
    23. [23]
      An audit of the laboratory diagnosis of cryptosporidiosis in England and Wales. — Chalmers RM, Atchison C, Barlow K, Young Y, Roche A, Manuel R Journal of medical microbiology (2015)
    24. [24]
      A highly divergent 33 kDa Cryptosporidium parvum antigen. — Jenkins MC, Widmer G, O'Brien C, Bauchan G, Murphy C, Santin M et al. The Journal of parasitology (2014)
    25. [25]
      Application of an ELISA-type screen printed electrode-based potentiometric assay to the detection of Cryptosporidium parvum oocysts. — Laczka O, Skillman L, Ditcham WG, Hamdorf B, Wong DK, Bergquist P et al. Journal of microbiological methods (2013)
    26. [26]
      Detection of Cryptosporidium parvum oocysts in calf fecal samples by direct immunofluorescence assay. — Teixeira WF, Coelho WM, Nunes CM, Meireles MV Revista brasileira de parasitologia veterinaria = Brazilian journal of veterinary parasitology : Orgao Oficial do Colegio Brasileiro de Parasitologia Veterinaria (2011)
    27. [27]
      Development of electrochemical based sandwich enzyme linked immunosensor for Cryptosporidium parvum detection in drinking water. — Thiruppathiraja C, Saroja V, Kamatchiammal S, Adaikkappan P, Alagar M Journal of environmental monitoring : JEM (2011)
    28. [28]
      Comparative efficacy of conventional primer sets in detection of Cryptosporidium parvum for diagnostic use. — Kar S, Daugschies A, Bangoura B Parasitology research (2010)
    29. [29]
      Morphology and in vitro infectivity of sporozoites of Cryptosporidium parvum. — Petry F, Kneib I, Harris JR The Journal of parasitology (2009)
    30. [30]
      Determination of the specificities of monoclonal and polyclonal antibodies to Neospora, Toxoplasma and Cryptosporidium by fluorescent antibody test (FAT). — Latif BM, Jakubek EB Tropical biomedicine (2008)
    31. [31]
      Alternative immunofluorescent labeling of Cryptosporidium parvum in water samples using semiconductor quantum dots. — Lee LY, Hu JY, Ong SL, Ng HY, Wong SW, Feng Y et al. Water environment research : a research publication of the Water Environment Federation (2008)
    32. [32]
      Inhibition of Cryptosporidium parvum infection of a mammalian cell culture by recombinant scFv antibodies. — Pokorny NJ, Boulter-Bitzer JI, Hall JC, Trevors JT, Lee H Antonie van Leeuwenhoek (2008)
    33. [33]
      Inactivation of Cryptosporidium parvum under chlorinated recreational water conditions. — Shields JM, Hill VR, Arrowood MJ, Beach MJ Journal of water and health (2008)
    34. [34]
      Modeling Cryptosporidium parvum oocyst inactivation and bromate formation in a full-scale ozone contactor. — Tang G, Adu-Sarkodie K, Kim D, Kim JH, Teefy S, Shukairy HM et al. Environmental science & technology (2005)
    35. [35]
      Optimised immunofluorescence procedure for enumeration of Cryptosporidium parvum oocyst suspensions. — Chesnot T, Marly X, Chevalier S, Estévenon O, Buès M, Schwartzbrod J Water research (2002)
    36. [36]
      Rapid methods to isolate Cryptosporidium DNA from frozen feces for PCR. — Ward LA, Wang Y Diagnostic microbiology and infectious disease (2001)
    37. [37]
      Cryptosporidium parvum infection stimulates the secretion of TGF-beta, IL-8 and RANTES by Caco-2 cell line. — Maillot C, Gargala G, Delaunay A, Ducrotte P, Brasseur P, Ballet JJ et al. Parasitology research (2000)
    38. [38]
      Detection of cryptosporidia and Cryptosporidium parvum oocysts in environmental water samples by immunomagnetic separation-polymerase chain reaction. — Hallier-Soulier S, Guillot E Journal of applied microbiology (2000)
    39. [39]
      Generation of a polyclonal Fab phage display library to the protozoan parasite Cryptosporidium parvum. — Baecher-Allan CM, Santora K, Sarantopoulos S, Den W, Sompuram SR, Sharon J et al. Combinatorial chemistry & high throughput screening (1999)
    40. [40]
      Enzyme immunoassay detection of Cryptosporidium parvum inhibition by sinefungin in sporozoite infected HCT-8 enterocytic cells. — Gargala G, Delaunay A, Favennec L, Brasseur P, Ballet JJ International journal for parasitology (1999)
    41. [41]
      Evaluation of fluorochromes for flow cytometric detection of Cryptosporidium parvum oocysts labelled by fluorescent in situ hybridization. — Deere D, Vesey G, Ashbolt N, Davies KA, Williams KL, Veal D Letters in applied microbiology (1998)
    42. [42]
      Viable Cryptosporidium parvum oocysts exposed to chlorine or other oxidising conditions may lack identifying epitopes. — Moore AG, Vesey G, Champion A, Scandizzo P, Deere D, Veal D et al. International journal for parasitology (1998)
    43. [43]
      The use of a ribosomal RNA targeted oligonucleotide probe for fluorescent labelling of viable Cryptosporidium parvum oocysts. — Vesey G, Ashbolt N, Fricker EJ, Deere D, Williams KL, Veal DA et al. Journal of applied microbiology (1998)
    44. [44]
      Detection of Cryptosporidia in different water sources in Alexandria by monoclonal antibody test and modified Ziehl Neelsen stain. — Youssef MY, Khalifa AM, el Azzouni MZ Journal of the Egyptian Society of Parasitology (1998)
    45. [45]
      Ribosomal RNA gene organization in Cryptosporidium parvum. — Le Blancq SM, Khramtsov NV, Zamani F, Upton SJ, Wu TW Molecular and biochemical parasitology (1997)
    46. [46]
      Efficacy of 101 antimicrobials and other agents on the development of Cryptosporidium parvum in vitro. — Woods KM, Nesterenko MV, Upton SJ Annals of tropical medicine and parasitology (1996)
    47. [47]
      Interaction of the human serine protease inhibitor alpha-1-antitrypsin with Cryptosporidium parvum. — Forney JR, Yang S, Healey MC The Journal of parasitology (1996)
    48. [48]
      Crude extract and recombinant protein of Cryptosporidium parvum oocysts induce proliferation of human peripheral blood mononuclear cells in vitro. — Gomez Morales MA, Ausiello CM, Urbani F, Pozio E The Journal of infectious diseases (1995)
    49. [49]
      Development of a microtitre ELISA to quantify development of Cryptosporidium parvum in vitro. — Woods KM, Nesterenko MV, Upton SJ FEMS microbiology letters (1995)
    50. [50]
      Immunofluorescent microscopical visualization of trails left by gliding Cryptosporidium parvum sporozoites. — Arrowood MJ, Sterling CR, Healey MC The Journal of parasitology (1991)
    51. [51]
      Sporozoites and merozoites of Cryptosporidium parvum share a common epitope recognized by a monoclonal antibody and two-dimensional electrophoresis. — Tilley M, Upton SJ The Journal of protozoology (1991)
    Share:TwitterRedditLinkedIn

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG